Jamieson Laboratories Acquires PanGeo Pharma Division

On August 19, 2003 Jamieson Laboratories Ltd. acquired the health care products division of PanGeo Pharma Inc., including the Wampole and Quest brands and all related intellectual property, as well as its manufacturing operations in Vancouver, for an aggregate purchase price of $21.2 million. This transaction was completed in the context of PanGeo Pharma’s restructuring pursuant to the Companies\' Creditors Arrangement Act. As part of the transaction, PanGeo Pharma has been granted by Jamieson Laboratories a three-year license to use Wampole trademarks in connection with PanGeo Pharma’s existing Wampole line of products.

Jamieson Laboratories was represented by Ogilvy Renault, with a team that included Robert Kozlov and Pierre Soulard (mergers and acquisitions), Michael Weinczok (insolvency and restructuring), Rowena Borenstein (intellectual property), David Bannon (labour and employment) and Peter Fairweather (real estate), and Sylvain Rigaud (insolvency and restructuring) and Marin Rochette (labour and employment) in Montreal.

PanGeo Pharma was represented by Gowling Lafleur Henderson LLP, with a team that included E. Patrick Shea, David Kolesar and Thomas Subic (insolvency and restructuring), Cliff Prophet (labour and employment) and Lisa Lifshitz (intellectual property) in Toronto, and Elyse Rosen and Guy Poitras (insolvency and restructuring) in Montreal. Ernst & Young Inc., the court appointed monitor and interim receiver, was represented by Borden Ladner Gervais LLP with a team led by Marc Duchesne, and including Clive Bird, Craig Hill, Magnus Verbrugge, Claudine Millette, Roger Jaipargas and Tanya Kozak.